Clinical Trials › NCT04130997
Active, Not RecruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Sponsored by TG Therapeutics, Inc.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 1100
Target enrollment
14
U.S. states
Nov 2019
Start date
May 2032
Expected completion
Interventions / Treatments
Ublituximab
Conditions studied
Relapsing Multiple Sclerosis (RMS)
Where this trial is running (19 sites)
Texas4 sites
Dallas · Frisco · Round Rock · +1 more
Florida2 sites
Miami · Tampa
Ohio2 sites
Columbus · Westerville
California1 site
Pasadena
Colorado1 site
Denver
Illinois1 site
Northbrook
Kansas1 site
Kansas City
Michigan1 site
Detroit
Nevada1 site
Las Vegas
New Jersey1 site
Teaneck
New Mexico1 site
Albuquerque
New York1 site
Amherst
Tennessee1 site
Knoxville
Washington1 site
Seattle
MS centers in Texas
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Texas centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
